Apremilast

Superiority:

Specification

Product Name:Apremilast
Product number:BJM-041
CAS:608141-41-9
Molecular formula:C22H24N2O7S
Molecular weight:460.5
Content:99.0%min

Alisa: Apremilast (CC-10004) ; Otezla

MW: 460.50

Density: 1.382 g/cm3
Boiling point: 741.342 °C at 760 mmHg
Flash point: 402.149 °C

Assay:99.0%min

Usage: Anti psoriatic arthritis ; PDE4 and TNF alpha inhibitors

Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis.Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. In September 2014, the USFDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.

Company information

Wuhan BJM Pharm Inc. was found in 2013, located in Hubei Province, where has long history, rich culture, convenient traffic, beautiful environment and preferential policy.

We have two factories in Dezhou , Shandong and Xianning, Hubei. The factory covers an area of 48,000 square meters with the building area of 26,000 square meters. We are specialized in the manufacture of pharmaceutical intermediates and cosmetic additives with good inspection equipments and innovative R & D capability.

In 2006, We established Lingxian Microworld Chemical New Material Co,.Ltd.

In 2008, We passed ISO quality system certificate

In 2013, We established Wuhan Benjamin Pharmaceutical Chemical Co.,Ltd , and obtain self-operation Import & Export right, mainly responsible for domestic and foreign business. At the same time, we set up R&D lab in Wuhan,Hubei province, can undertake various custom synthesis of intermediates and APIs.

In 2016,  obtain a registered trademark “ BJM ”.

In 2017, we applied for the invention patent of TRIS, and in 2018, we applied for the invention patent of ERDOSTAN intermediate（DL-HOMO）. At present, we have6 patents passed the preliminary examination, and 4 patents are under examination and approval.

In 2019, we purchased a R&D and office building with a total area of 2500 square meters, as our headquarters in Wuhan.

In 2020, we registered BJM Pharm Yunmeng Co., Ltd,  and the new production base settled in Geputan chemical park with  a total area of 50000 square meters.

We are specialized in the R&D ,production and sales of Erdosteine ,Pirfenidone, Telmisartan, Letrozole , Sitagliptin phosphate, Dapagliflozin , Tris , IPTG and related intermediates.

We stick to the principle as: people-oriented, customer first, Hope to establish a win-win business relationship with all friends